Skip to content
MarketScale
‹ Back to IndustriesSciences

HOW TO COMBINE PROBIOTICS AND PREBIOTICS TO MAXIMIZE THEIR BENEFITS

Probiotics, living microorganisms like yeasts and bacteria in our intestines, promote digestive health, support a healthy immune system, and can help reduce the unwanted effects of bloating, gas, or diarrhea. Prebiotics, on the other hand, employ the non-digestible fibers or starches commonly found in legumes, whole wheat foods, onions, cabbages, asparagus, and oatmeal to help…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · Promoted Content
Share
HOW TO COMBINE PROBIOTICS AND PREBIOTICS TO MAXIMIZE THEIR BENEFITS

Key takeaways

01

Probiotics, living microorganisms like yeasts and bacteria in our intestines, promote digestive health, support a healthy immune system, and can help reduce the unwanted effects of bloating, gas, or diarrhea.

02

Prebiotics, on the other hand, employ the non-digestible fibers or starches commonly found in legumes, whole wheat foods, onions, cabbages, asparagus, and oatmeal to help…

Probiotics, living microorganisms like yeasts and bacteria in our intestines, promote digestive health, support a healthy immune system, and can help reduce the unwanted effects of bloating, gas, or diarrhea. Prebiotics, on the other hand, employ the non-digestible fibers or starches commonly found in legumes, whole wheat foods, onions, cabbages, asparagus, and oatmeal to help probiotic microorganisms flourish. In addition, novel prebiotics, such as lactoferrin, almond lipids and bacteriophages are being identified. Synbiotics, supplements that combine probiotics and prebiotics in a powerful synergy, can maximize the beneficial effects of both.

Prebiotics Help Probiotics Survive and Thrive

Probiotic supplements contain live microorganisms that enhance health by improving the balance of microflora or microorganisms in the gastrointestinal tract. But to be effective, probiotics must survive the stomach’s acidic environment, as well as bile and pancreatic secretions into the small intestine. Once they survive, probiotics then compete for nutrients with harmful bacteria in the gut.

Prebiotic supplements help maintain digestive balance while supplying the required nutrition probiotics need to thrive. A prebiotic is defined as a non-digestible food ingredient that beneficially affects the host by selectively stimulating the growth and activity of a limited number of bacteria in the colon. This implies that each individual prebiotic may stimulate the growth and activity of some probiotics but not others. The key is careful selection of the appropriate prebiotic that improves the functionality of each probiotic.

Synbiotics Provide the Right Combination of Prebiotics and Probiotics

There is a right way to combine selected probiotics and prebiotics into an optimal product supplement that feeds the human biome. Many common fiber-based prebiotics have the unfortunate side effect of feeding both good and bad bacteria. In addition, they typically require massive doses to be effective – doses which won’t even fit into a single capsule – and may cause gas and digestive discomfort. An ideal synbiotic, on the other hand, should combine the correct prebiotics in the exact proportions necessary to maximize the desired beneficial health effects of specific probiotic strains by stimulating the growth and activating the metabolism of a limited number of health-promoting bacteria. In this way, synbiotic products improve the survival of live microbial supplements in the gastrointestinal tract. When the synergistic effect is optimized between prebiotics and probiotics, the beneficial effects of each are optimized.

Probiotics and Prebiotics Together Make a Dynamic Duo

Enzymes alone are good, enzymes plus probiotics are better, and enzymes, probiotics, and prebiotics together are best. Enzymes help drive the nutritional uptake of the food while the probiotics ensure a good digestive balance and flora. Deerland Probiotics & Enzymes developed the novel prebiotic, PreforPro, to further enhance the health benefits of these supplements. More than 20 studies have been performed to confirm the safety and efficacy of PreforPro in promoting the growth of a broad spectrum of probiotic species while crowding out undesirable bacteria.

Learn more about the prebiotic power of PreforPro by visiting https://www.deerlandenzymes.com/preforpro/ today.

Read more at deerlandenzymes.com

About the author

PC
Promoted Content

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512